Abstract
The invention relates to use of specific peptides derived from the cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. The invention further relates to compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
| Original language | American English |
|---|---|
| Patent number | EP3211002 |
| IPC | C07K 14/ 705 A I |
| Priority date | 14/03/13 |
| State | Published - 30 Aug 2017 |